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Platelets are anucleate blood cells that play a crucial role in the maintenance of hemosta-
sis. While platelet activation and elevated platelet counts (thrombocytosis) are associated
with increased risk of thrombotic complications, low platelet counts (thrombocytopenia)
and several platelet function disorders increase the risk of bleeding. Over the last years,
more and more evidence has emerged that platelets and their activation state can also
modulate innate and adaptive immune responses and low platelet counts have been iden-
tified as a surrogate marker for poor prognosis in septic patients. Viral infections often
coincide with platelet activation. Host inflammatory responses result in the release of
platelet activating mediators and a pro-oxidative and pro-coagulant environment, which
favors platelet activation. However, viruses can also directly interact with platelets and
megakaryocytes and modulate their function. Furthermore, platelets can be activated by
viral antigen–antibody complexes and in response to some viruses B-lymphocytes also gen-
erate anti-platelet antibodies. All these processes contributing to platelet activation result in
increased platelet consumption and removal and often lead to thrombocytopenia, which is
frequently observed during viral infection. However, virus-induced platelet activation does
not only modulate platelet count but also shape immune responses. Platelets and their
released products have been reported to directly and indirectly suppress infection and to
support virus persistence in response to certain viruses, making platelets a double-edged
sword during viral infections. This review aims to summarize the current knowledge on
platelet interaction with different types of viruses, the viral impact on platelet activation,
and platelet-mediated modulations of innate and adaptive immune responses.
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INTRODUCTION
From an evolutionary perspective, the cellular mediators of hemo-
stasis and immune defense have not always been separated. In
invertebrates, a cell type called hemocyte protects the host from
invading microbes and the same cell also prevents “blood” (i.e.,
hemolymph) loss upon injury by triggering coagulation (1, 2).
In highly developed species, hemostasis and immune response
have been divided and leukocytes resume the immune response
functions, while platelets maintain hemostasis (2).
For decades, these two systems were thought to act indepen-
dently, but this concept has recently been challenged. Emerging
evidence suggests that the boundaries between coagulation and
immune defense are actually not as clear-cut as originally sup-
posed. A new concept of involvement of immune cells in hemo-
stasis, termed immunothrombosis, has been recently proposed,
which assumes a function of innate immune cells in thrombosis
(3). On the other hand, an important role of platelets in immune
response becomes more and more apparent (4–7).
In 1882, Bizzozero discovered platelets as the third morpholog-
ical element in blood and elucidated the function of these cells in
hemostasis and thrombosis (8). For a long time, platelets and their
granule content were thought to mainly mediate the activation of
the coagulation system and the recruitment of further platelets
to stop blood loss upon injury. Unwanted platelet activation was
noted to occur as a response to internal injuries, for example,
denudation and erosion of the endothelial surface or rupture of an
atherosclerotic plaque (9). Consequently, platelets were assumed
to be responsible for the lethal steps of cardiovascular diseases,
where unstable thrombi occlude small vessels, thereby compro-
mising oxygen supply of target organs. Nevertheless, platelets are
involved in far more processes and they respond to and inter-
act with far more triggers than initially thought. Besides their
central role in hemostasis, platelets assist and modulate inflamma-
tory reactions and immune responses by direct interaction with
leukocytes as well as endothelial cells and via release of soluble
inflammatory mediators that enhance recruitment of leukocytes
and trigger their activation (2, 4, 6, 10). Platelets also express sur-
face receptors, such as lectins, integrins, and toll-like receptors
(TLR), allowing them to directly interact with several pathogens.
Moreover, they express Fc receptors by which they can recognize
immunocomplexes.
Thus, platelet activation does not only occur in response to
injury and is not only limited to hemostatic processes but also
modulates host response and virus survival (3–5, 7, 10–12).
Therefore, potential immune-modulatory side effects should be
considered during anti-platelet therapy.
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To date, the role of platelets in response to invading pathogens
is not fully understood. Platelet–microbe interactions seem to be
beneficial for the host due to up-regulation of immune responses.
However, platelet interaction with invading pathogens is also spec-
ulated to benefit virus or bacteria, as platelets provide shelter
against leukocytes, antiviral agents, and antibiotics. Moreover, the
stickiness of platelets might attenuate microbe–endothelial inter-
actions and facilitate infection by similar mechanisms to those
recently described for platelet interactions with circulating tumor
cells (13).
This review aims to summarize the current knowledge on
platelet interaction with different types of viruses, the viral
impact on platelet activation, and platelet-mediated modulations
of innate and adaptive immune responses.
MECHANISMS OF VIRUS-INDUCED THROMBOCYTOPENIA
Platelets are, after erythrocytes, the second most abundant cell
population in the blood. Normal platelet counts range from
150,000 to 450,000 platelets per microliter. Thrombocytope-
nia, which represents a drop in platelet count caused by either
decreased platelet production or increased platelet destruction, is
associated with an increased bleeding risk. Thrombocytopenia is
frequent following viral infections and viruses use a variety of
distinct strategies to decrease the levels of circulating platelets.
The different mechanisms of how virus infection can interfere
with platelet production and might trigger platelet destruction
are summarized in the first chapter and Figure 1. As virus-
mediated thrombocytopenia is often multifactorial and differs
between virus infections, the mechanisms by which viruses trigger
FIGURE 1 | Mechanisms of virus-induced thrombocytopenia:
thrombocytopenia occurs either via decreased platelet production or
increased platelet destruction. Viruses can trigger a decrease in platelet
production by (I) infection of megakaryocytes, which can lead to
(A) apoptosis of megakaryocytes, (B) decreased maturation and ploidy of
megakaryocytes, or (C) decreased expression of thrombopoietin receptor
c-Mpl. Viruses can also infect hematopoietic stem cells (II), which results
(A) in a decrease of progenitor cells and (B) the induction of growth
deficient megakaryocyte colony forming units, due to disturbed cytokine
production by the infected cells in the bone marrow. Viruses can further
indirectly influence platelet production (III) via induction of IFNα/β, which
suppresses proplatelet formation or (IV) by targeting and modulating liver
functions, which are important for the production of megakaryocyte
growth and development factor thrombopoietin. Another mechanism for
how viruses cause thrombocytopenia is by favoring platelet destruction,
which frequently occurs during viremia. Viruses can either (V) directly
interact with platelets or (VI) platelets recognize immunocomplexes of
IgGs and viral antigens. Antiviral antigens often show cross-reactivity with
platelet surface integrins (VII), which provides another mechanism of
virus-induced destruction of platelets. The virus-induced pro-inflammatory
environment itself often leads to further platelet activation in viremic
patients (VIII). Additionally, changes in the portal vein pressure (IX) and an
enlarged spleen (X) can serve as trigger for platelet activation. Once
activated, platelets are recognized by circulating leukocytes or by cells in
spleen and liver and rapidly cleared from the circulation. IFN, interferon,
TPO, thrombopoietin; FcγRII, Fc receptor γ R II.
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thrombocytopenia are separately discussed for the most promi-
nent viruses and an overview on the receptors involved in direct
platelet–virus interactions is depicted in Figure 2.
DECREASED PLATELET PRODUCTION
Platelets are produced in the bone marrow by megakaryocytes,
which develop from hematopoietic stem cells. Megakaryocytes
first undergo linage commitment, followed by endomitosis result-
ing in polyploidy (14). Polyploidy is a state where one cell com-
prises multiple sets of chromosomes and this represents an impor-
tant step in megakaryopoiesis. After endoplasmatic maturation,
megakaryocytes form proplatelets, which bud off thousands of
platelets and microparticles into the blood stream (15). Megakary-
opoiesis is triggered by a variety of cytokines (e.g., GM-CSF, IL-3,
IL-6, IL-11, FGF4, and SDF-1), with thrombopoietin (TPO) being
the most important. Nevertheless, TPO does not only trigger
megakaryocyte development but also fulfils an important role in
maintaining stem cells (16).
Viruses can modulate platelet production at various steps of
development. They are able to influence the cytokine profile of the
host, resulting in altered TPO production in the liver. Examples
of this include: simian immunodeficiency virus (SIV), which trig-
gers TPO production via up-regulation of tumor growth factor
(TGF) β (17); human herpes virus 6, which can interfere with
TPO-inducible megakaryocytic colony formation (18); human
FIGURE 2 | Platelet receptors for viruses: platelets and viruses can
directly interact via a plethora of surface receptors. CMV binds to
platelets via TLR2, EMCV interacts via TLR7, rotavirus utilizes GPIa/IIa to
bind to platelets and hantavirus and adenovirus interact with platelets via
GPIIb/IIIa. EBV–platelet interaction occurs via CR2. HIV and DV bind to
lectin receptors such as CLEC-2 and DC-SIGN. HIV further interacts with
CXCR4 and CCL3 and CCL5. Platelets express the Coxsackie virus-specific
receptor, CAR, and HCV interacts with platelets via GPVI. CAR,
Coxsackie-adenovirus receptor; CLEC-2, C-type lectin domain family 2; CCL,
chemokine (C–C motif) ligand; CMV, cytomegalovirus; CR, complement
receptor; CXCR4, C–X–C chemokine receptor type 4; EBV, Epstein–Barr
virus; EMCV, encephalomyocarditis virus; DC-SIGN, dendritic cell-specific
intercellular adhesion molecule-3-grapping non-integrin; DV, Dengue virus;
FcγRII, Fc receptor γ II; GP, glycoprotein; HCV, hepatitis virus C; HIV, human
immunodeficient virus; IgG, immunoglobulin G; TLR, toll-like receptor;
herpes virus 7, which impairs the survival and differentiation of
megakaryocytes (19).
Some viruses also directly interfere with TPO production by
destruction of liver tissue as shown for hepatitis C virus (HCV)
(20). The resulting drop in TPO production results in delayed
megakaryocyte development and a decrease in platelet production.
Other viruses infect bone marrow stromal cells and hematopoietic
stem cells, resulting in altered cytokine production and decreased
number of progenitor cells, thereby disturbing hematopoiesis (21).
Human immunodeficiency virus (HIV), cytomegalovirus
(CMV), and HCV are known to replicate in megakaryocytes (22–
24) and many more viruses can interact with megakaryocytes
modulating their proliferation and function (23, 25–29). Viral
infection of megakaryocytes can increase apoptosis and decreases
the maturation and ploidy of megakaryocytes. Moreover, virus-
infected megakaryocytes have been shown to express less surface
c-Mpl, which is the receptor for TPO (30). An overview on the
different mechanisms on how viruses can interfere with platelet
production is depicted in Figure 1.
ENHANCED PLATELET DESTRUCTION
While thrombocytopenia induced by decreased platelet produc-
tion is observed at later stages of infection, rapidly induced
thrombocytopenia in response to viral infections is mediated via
enhanced platelet destruction.
The most rapid way of platelet destruction occurs via direct
interaction between platelets and viruses. Platelet–virus interac-
tion can occur via a variety of receptors and are mainly mediated
by integrins, surface lectins, and TLR (25, 31, 32) (see Figure 2).
Platelets can bind CMV via TLR2, which triggers platelet activa-
tion and degranulation and results in enhanced platelet interac-
tion with neutrophils (32). Encephalomyocarditis virus (EMCV)
was recently shown to interact with platelet TLR7, which also
leads to platelet degranulation and direct platelet–neutrophil
interactions (33). Platelet fragments subsequently get phagocy-
tized by neutrophils, thereby contributing to the drop in platelet
count (33).
Rotavirus utilizes the collagen receptor GPIa/IIa to bind to
platelets (25, 34), while hantavirus and adenoviruses interact
with platelets via the fibrinogen receptor GPIIb/IIIa (35). How-
ever, GPIIb/IIIa does not seem to be the unique receptor for
platelet–adenovirus interaction, as inhibition of GPIIb/IIIa does
not alter platelet internalization of adenoviruses (36). In addi-
tion, hantavirus-infected endothelial cells can bind to quiescent
platelets via GPIIb/IIIa (37), which results in platelet activation
and clearance but might also influence vascular permeability (38).
GPIIb/IIIa is the most abundant platelet integrin and displays
bi-directional signaling functions. Inside-out signaling, which is
positively regulated by various platelet agonists, is mediated by
intracellular protein–protein interactions and biochemical reac-
tions that regulate GPIIb/IIIa affinity (39). These intracellular
processes triggering GPIIb/IIIa activation are complex and include
recruitment of talin, which separates the GPIIb and the GPIIIa
subunits, and kindlins, which are involved in GPIIb/IIIa activa-
tion (40) independent of talin recruitment (41). Further, G protein
subunit Gα13 directly binds to the cytoplasmic domain of GPIIIa
and promotes ligand binding to GPIIb/IIIa (42).
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Outside-in signaling via receptor binding promotes actin poly-
merization and platelet spreading (39) and can thereby enhance
virus attachment to endothelial cells but also promote platelet
clearance.
Epstein–Barr virus (EBV) interaction with platelets occurs via
complement receptor 2 (CR2) (43). HIV and dengue virus acti-
vate platelets by binding to lectin receptors such as C-type lectin
domain family 2 (CLEC-2) and cell-specific intercellular adhe-
sion molecule-3-grapping non-integrin (DC-SIGN) (44). Platelets
and/or megakaryocytes can further interact with HIV envelope
proteins via C–X–C chemokine receptor type 4 (CXCR4) or
via chemokine (C–C motif) ligand (CCL) 3 (MIP-1α) and 5
(RANTES) (25). However, HIV-1 changes its co-receptor usage
from CCR5 to CXCR4 only after many years of infection and
this receptor change represents a switch to non-CD4-dependent
platelet activation at late stages of disease.
In addition, platelets express the Coxsackie virus-specific
Coxsackie-adenovirus receptor (CAR) (45) and HCV interacts
with platelets via collagen receptor GPVI (46).
These direct interactions often result in platelet activation
and adhesion of activated platelets to leukocytes. Platelet bind-
ing to neutrophils triggers phagocytosis of platelets (33, 47) and
platelet activation itself promotes platelet clearance in spleen and
liver (48).
However, platelets are not only activated by direct interactions
with viruses. Host defense mechanisms in response to viral infec-
tions can also lead to platelet activation. For example, many viral
infections lead to systemic inflammation, which in turn triggers
platelet activation and decreases platelet life span (49). Among
others, influenza virus, rhinovirus, and CMV infection result in
up-regulation of cytokines, such as interleukin 6 (IL-6), in target
cells (50).
Platelets can be activated by these cytokines, leading to platelet–
leukocyte interactions, which foster leukocyte and endothelial acti-
vation, further amplifying platelet activation and enhancing their
clearance by splenic macrophages or Kupffer cells in the liver (45).
Monocytes that encounter dengue virus, for example, start gener-
ating platelet activating factor (PAF) (51), which is a lipid mediator
that triggers platelet activation. This leads to enhanced apoptosis
of platelets and accelerates platelet clearance in secondary dengue
infection (52).
Several virus infections activate the coagulation cascade via
induction of tissue factor (TF) expression in target cells. Gen-
eration of thrombin by the activated coagulation cascade causes
platelet activation and subsequent clearance via protease activating
receptor (PAR) signaling (53). PARs on platelets, endothelial cells,
and leukocytes are important modulators during viral infections,
which modulate innate immune responses and exert positive and
negative effects on TLR-dependent responses (53).
Platelets also recognize viral particles coated with immunoglob-
ulins via their FcγRII receptor, which results in Fc receptor-
mediated platelet activation, aggregation, and platelet clearance
(54, 55). FcγRII-mediated platelet activation depends on IgG and
GPIIb/IIIa engagement and involves ADP and thromboxane A2
(TxA2) feedback mechanisms to cause platelet aggregation, which
is further enhanced by CXCL4 (56).
Furthermore, B-lymphocyte production of antibodies against
some viruses has been shown to interfere with platelet survival.
These antibodies, which usually target surface glycoproteins of
viruses, show a cross-reactivity with platelet surface intergrins such
as GPIIb/IIIa or GPIb-IX-V (38). This so called idiopathic throm-
bocytopenic purpura (ITP) or platelet autoantibody-induced
thrombocytopenia has been described for HCV, HIV, CMV, EBV,
hantavirus, varicella zoster virus, herpes viruses, and severe acute
respiratory syndrome coronavirus (38).
Additionally, platelet destruction in response to viral infections
can occur due to disturbed portal vein pressure and enhanced
sequestration of platelets by the enlarged spleen as is the case in
HCV infection (57).
MULTIFACTORIAL MECHANISMS LEADING TO
THROMBOCYTOPENIA
Thrombocytopenia in response to viral infections is often multi-
factorial. In viral hepatitis, thrombocytopenia is caused by platelet-
specific glycoprotein antibodies (58) as well as by immune com-
plexes bound to the platelet surface (59). In the case of HCV,
thrombocytopenia can be reversed using a selective thrombin
receptor agonist (60), indicating that coagulation, inflammation,
and platelet activation play a role in HCV-induced decrease of
platelet count. HCV also indirectly affects megakaryopoiesis (25,
59). HCV-induced liver dysfunction results in a decrease in TPO
production, which in turn results in impaired platelet produc-
tion in the bone marrow (20). The recovery of TPO levels and
increase in platelet count following successful liver transplanta-
tions in HCV-infected individuals (20) emphasizes the importance
of this mechanism in HCV-induced thrombocytopenia. More-
over, portal hypertension leads to platelet activation and shortens
platelet survival due to increased splenic platelet sequestration
(57). However, treatment aiming at reversing portal hypertension
did not always correct thrombocytopenia (20).
Human immunodeficiency virus-induced thrombocytopenia
is caused by multiple mechanisms. The effects of HIV on
megakaryocyte development were recently reviewed in Ref. (30).
In brief, HIV results in impaired survival of bone marrow
megakaryocytes and their precursors. HIV also decreases the
number and activity of human progenitor cells and decreases
megakaryocyte maturation and ploidy. HIV surface glycopro-
tein gp120 leads to increased megakaryocyte apoptosis in vitro
due to increased TGFβ and down-regulation of the proliferation-
inducing ligand tumor necrosis factor ligand superfamily mem-
ber 13 (TNFSF13). Further, gp120 interacts with CD4, which is
expressed by immature megakaryocytes, which also express CCR5,
and leads to their infection (61). Furthermore, HIV infection
of megakaryocytes can lead to reduced TPO receptor (c-Mpl)
expression.
In dengue virus infection, platelet production is impaired by
suppression of megakaryopoiesis via infection of hematopoi-
etic progenitor cells or indirectly via altered cytokine levels in
the bone marrow due to impaired stromal cell function (51).
Platelets from patients with dengue infection present signs of
activation, mitochondrial dysfunction, and enhanced apopto-
sis, which may contribute to the genesis of thrombocytopenia
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(62, 63). Further, enhanced destruction of platelets occurs due
to cross-reaction of platelets with anti-dengue virus antibod-
ies. Dengue virus-induced anti-non-structural protein-1 (NS-1)
induces complement-mediated lysis of platelets and thereby fur-
ther accelerates thrombocytopenia (64). NS-1 can also activate
endothelial cells and leads to increased vascular permeability and
further platelet activation (65). Dengue virus-infected patients
show increased levels of E-selectin on their endothelial cell sur-
face, which promotes adhesion and clearance of platelets (65, 66)
as well as enhanced activation of the coagulation cascade (67).
Arenaviruses infection by either lymphocytic choriomeningi-
tis virus (LCMV) or Junin virus results in thrombocytopenia and
decreased agonist-induced platelet responses in mice (68, 69). As
a consequence, platelet depletion in LMCV-infected mice results
in lethal hemorrhagic anemia (68). This effect is caused by dimin-
ished platelet responses, rather than solely a drop in platelet count.
The underlying mechanism of altered platelet production and
reduced platelet reactivity was found to rely on virus-induced pro-
duction of interferon (IFN) α/β (68, 69). Junin virus mainly infects
CD34+ cells not megakaryocytes but impairs proplatelet forma-
tion and platelet release via IFNα/β receptor signaling (69). IFNα/β
receptor signaling represents an important paracrine repressor
of megakaryopoiesis, which directly inhibits TPO-induced sig-
naling through induction of suppressor of cytokine signaling
1 (SOCS-1) (70), induction of 2′5′-oligoadenylate synthetase
(OAS) (68), and decease of nuclear factor erythroid 2 (NF-E2)
expression (69).
Hantavirus can directly interact with and activate platelets via
GPIIb/IIIa (35) and infection of megakaryocytes with hantavirus
induces the up-regulation of human leukocyte antigen (HLA) class
1 molecules on the megakaryocyte surface, which leads to cytotoxic
T-lymphocyte-mediated destruction of megakaryocytes (27).
Viruses also possess enzymes, which can modulate platelet
functions. For example, Influenza virus exhibits neuraminidase
(sialidase), which hydrolyses the terminal sialic acid residues from
host cell receptors and thereby decreases the life span of platelets by
targeting platelets for rapid clearance in the liver and spleen (71).
As another example, mycoviral neuraminidase has been shown to
reduce platelet life span by cleaving sialic acid in the platelet mem-
brane (72). Besides the effect on platelet live span, neuroaminidase
further alters megakaryocyte ploidy as well as morphology and size
of platelets (73). Newcastle virus can directly disrupt platelet cell
membrane, resulting in platelet lysis (74). Human parvovirus 19
cannot reproduce in megakaryocytes, but triggers a drop in platelet
count via platelet activation (75).
Despite its effects on TPO generation, direct interaction of the
non-human SIV with platelets results in platelet–monocyte aggre-
gate formation, which promotes monocyte differentiation into a
more inflammatory phenotype. Furthermore, platelet activation
triggers clearance of platelets (76, 77) as platelets become recog-
nized by macrophages in the spleen, leading to a rapid drop in
platelet count.
It is currently unclear if, and to what extent, viruses or the host
could benefit from thrombocytopenia. It has been suggested that
down-regulation of hematopoiesis, for example, in dengue virus
infection might have a protective role for the microenvironment
to limit injury during elimination of infected cells (78).
ANTIVIRAL EFFECTS OF PLATELETS
Direct interaction between platelets and viruses has been observed
in various viral infections and could be proven by in vitro studies.
The interactions leading to platelet activation do not only result
in enhanced platelet clearance, the elimination of virus-laden
platelets also contributes to the clearance of virus particles (25).
An overview on the different mechanisms by which platelets
can interfere with virus infection is given in Figure 3. Platelet
activation in response to direct and indirect interaction with
viruses results in platelet activation and degranulation. Platelet
α-granules provide platelet-mediated host defense mechanisms,
as they contain kinocidins and microbicidal proteins important
for antiviral host defense. Kinocidins have immune-modulatory
functions including chemotaxis and activation of various immune
cells (79). They can differentiate between host and pathogen cell
membranes and distinct microbial spectra under different pH con-
ditions. Thrombin, which is produced upon inflammation and
injury, can proteolytically cleave kinocidins and platelet antimi-
crobial peptides resulting in cleavage products with a stronger and
broader range of antimicrobial activity (49, 80). Pathogens can
also cleave kinocidins on distinct sites, which potentially results in
their inactivation.
The most abundant platelet kinocidin is platelet factor 4 (PF-
4/CXCL4). CXCL4 is released into the blood stream upon tissue
injury, inflammation, oxidative stress, or pathogen stimulation
such as platelet–virus interactions. CXCL4 has been identified as
a broad-spectrum HIV-1 inhibitor and suppresses HIV-1 infec-
tion of T-lymphocytes via steric inhibition by binding of CXCL4
proximal to the CD4 binding site on gb120 (81, 82).
Other important chemokine released during viral infections in
host defense are CCL5 and CCL3 (83). CCL5 and CCL3 have
been identified as major HIV-suppressive factors produced by
cytotoxic T-lymphocytes (84) and also platelet-derived CCL5 and
CCL3 could play a role in this process. It is currently unclear
whether the effect of CCL5 on inhibiting HIV infection is due
to perturbation of the viral envelope and/or due to competitive
binding to its receptors (primarily CCR5) (79). HIV gp41 is able
to decrease CCL5 release from platelets, thereby directly coun-
teracting the antiviral responses of platelets (85). While CXCL4
is mainly platelet-derived, CCL5 can be released by various cells
types and indeed, a variety of viruses has been shown to induce
CCL5 release [reviewed in Ref. (86)].
CCL5 is further involved in viral lung diseases (87). It represents
an important chemokine during the development and resolution
of a pulmonary leukocyte response to influenza A virus infection
in mice (88). CCL5 interaction with its receptor CCR5 provides
an anti-apoptotic signal for macrophages during influenza virus
infection (89) and is important for cell survival during viral infec-
tions. CCL5 has multifaceted roles in HCV infection, as it mod-
ulates inflammatory reactions and tissue injury and also induces
the up-regulation of T-lymphocyte helper cells type 1 (Th1) (90).
Upon activation, platelets release β-defensins, which have been
shown to neutralize a variety of viruses (91). Platelet antimicrobial
peptides PD3 (KNGRKLCLDLQAALY) and PD4 (AALYKKKI-
IKKLLES), which are platelet α-granule-derived molecules, have
also been demonstrated to potently reduce viral titers of vaccinia
virus (92). Other platelet-derived antimicrobial peptides, for
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FIGURE 3 | Effects of activated platelets on virus infection: upon
activation, platelets release their α-granules, containing high amounts of
CXCL4, which up-regulates coagulation and leukocyte recruitment.
Moreover, CXCL4 decreases HIV infection but also enhances liver fibrosis.
CCL5, another α-granule-derived chemokine, also decreases HIV infection and
enhances Th1 lymphocyte responses in HCV infection and serves as a survival
signal for macrophages in influenza infection. Platelets release PMPs and
β-defensins from their α-granules, which mediate virus neutralization. They
protect splenocytes from necrosis in LCMV infection. Platelet dense granules
contain 5-HT, which enables liver regeneration but also HBV and HCV
infection. Platelet activation leads to the expression and release of CD154 and
CD62P, which allow direct interaction between platelets and leukocytes.
Platelet interaction with B-lymphocytes enhances germinal center formation
and antiviral IgG production. Platelets trigger T-lymphocyte differentiation and
cytotoxicity as well as survival and differentiation of monocytes. In
neutrophils, platelet adhesion stimulates ROS production and boosts
phagocytosis. Platelet interaction with dendritic cells promotes their
maturation and facilitates antigen presentation. Finally, platelet activation
results in interaction and activation of further platelets, which triggers platelet
aggregation and amplifies the above described processes. CCL5, chemokine
(C–C motif) ligand 5; CXCL4, C–X–C chemokine ligand 4, GP, glycoprotein;
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficient
virus; IgG, immunglobulin G; LCMV, lymphocytic choriomeningitis; PMPs,
Platelet antimicrobial peptides; PSGL-1, P-selectin (CD62P) glycoprotein
ligand-1; sCD154, soluble CD154/CD40 ligand; Th1, T-helper lymphocyte type
1; 5-HT, serotonin.
example, thymosin beta 4, CXCL7, or cleavage products of antimi-
crobial peptides (fibrinopeptide A and B, thrombocidins), do not
directly act against viral infections but could prevent the host from
bacterial super-infections (49).
The highest amounts of serotonin in blood are stored in
platelet dense granules, which are also released upon platelet acti-
vation. Serotonin was found to be an important mediator of
liver regeneration (93, 94) and also mediates early T-lymphocyte
stimulation (95).
Platelet degranulation further results in surface expression of
P-selectin, which is part of the inner α-granule membrane, which
fuses with the outer platelet membrane upon granule exocytosis.
P-selectin interacts with its counter-receptor P-selectin glycopro-
tein ligand-1 (PSGL-1), which is constitutively expressed on the
surface of leukocytes (96). Platelet interactions with leukocytes
mediate immune responses during viral infections (79). Direct
interaction with platelets leads to activation of leukocytes, result-
ing in enhanced phagocytosis and reactive oxygen production of
neutrophils, as well as neutrophil extracellular trap formation. The
platelet–monocyte interaction results in an increased activation
and differentiation and boosts monocyte surface expression of TF
and formation of microparticles (96).
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FIGURE 4 | Adverse effects of platelets in viral infections: platelets
can shelter viruses like HIV, HVC, HBV, and influenza and facilitate
their transportation throughout the circulation, thereby enabling de
novo infections at distal sites. Platelet–virus interaction often results in
platelet activation and subsequent release of α-granules and dense
granules. CXCL4 from α-granules has been demonstrated to enhance
HIV infection of macrophages and enhance liver fibrosis in hepatitis.
CCL5 enhances T-lymphocyte recruitment and thereby promotes HIV
infection of T-lymphocytes. Dense granule-derived 5-HT was shown to
boost HBV and HCV infection by decreasing the entry of cytotoxic
T-lymphocytes. Direct interaction of platelets with leukocytes facilitates
infection of leukocytes and enhances both leukocyte activation and
inflammation. Activation of platelets leads to activation and recruitment
of further platelets and enhances pro-coagulatory processes.CCL5,
chemokine (C–C motif) ligand 5; CXCL4, C–X–C chemokine ligand 4, GP,
glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficient virus; sCD154, soluble CD154/CD40 ligand; 5-HT,
serotonin.
In response to CMV and EMCV, platelet–virus interaction
results in stimulation of TLRs, which trigger platelet degranula-
tion and rapid direct interaction of platelets and neutrophils (32,
33). Of note, platelets were shown to decrease EMCV counts in a
TLR7-dependent fashion and contribute to host survival while
no pro-thrombotic consequences of platelet TLR7 and EMCV
interaction could be observed (33).
Platelets recruit dendritic cells to sites of injury or infection (97)
and products released from platelets promote maturation of den-
dritic cells and enhance their antigen presenting capacity (98, 99).
Platelet–leukocyte interaction and modulation of leuko-
cyte functions can be further accelerated by CD40 ligand
(CD40L/CD154) binding to CD40. Platelets express and secrete
(soluble) CD154, thereby triggering host responses and boosting
inflammation.
Platelets directly interact with T-lymphocytes and B-
lymphocytes and modulate their function via direct cell–cell
interaction as well as soluble mediators (100). Platelet-released
CXCL4 and CCL5 enhance pro- and anti-inflammatory cytokine
production of T-lymphocytes (101). CXCL4 represents an impor-
tant mediator in T-cell differentiation, which leads to an
increase in regulatory T-lymphocytes (102) and limits Th17
differentiation (103).
Platelets additionally enhance T-lymphocyte-mediated ger-
minal center formation (104) and they can independently up-
regulate adenovirus specific IgGs via CD154 (105).
Binding of IgG-coated viruses causes platelet expression of
CD154 and CCL5, which in turn primes protective T-cell-
mediated immunity (79). Platelets in mice infected with lym-
phocytic choriomeningitis virus were found to be responsible for
efficient cytotoxic T-cell responses, which depended on platelet
GPIIIa (CD61) and CD154 (68). T-lymphocyte interaction with
platelets also results in the activation of platelets, which amplifies
the release of CCL5 (106).
In hepatitis virus B (HBV) infected mice, platelets were shown
to be responsible for the intra-hepatic accumulation of virus-
specific cytotoxic T-lymphocytes (107) and to mediate cytotoxic
T-cell influx into liver tissue via P-selectin, which enhances viral
clearance but also tissue damage (108). It was further shown
an LCMV infection model that a drop in platelet count leads
to necrotic destruction of splenocytes (109). This affects innate
and adaptive immunity and leads to uncontrolled LCMV repli-
cation (109), indicating that platelets are necessary to maintain
splenocyte survival.
ADVERSE EFFECTS OF PLATELET ACTIVATION IN VIRAL
INFECTIONS
To date, it remains unclear if platelet–virus interactions are benefi-
cial for the host or for the virus. Potential adverse effects of platelets
in viral infections are summarized in Figure 4. HIV, for example,
is internalized by platelets, which results in sheltering of virus par-
ticles from the host immune systems and allows dissemination
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throughout the entire body [reviewed in Ref. (25)]. Moreover, in
response to HIV interaction, platelets become activated and release
CCL5, which results in the recruitment of highly susceptible target
cells like T-lymphocytes and monocytes. It was demonstrated for
influenza virus that platelets serve as a carrier for the virus in the
circulation (72). Also HCV has been shown to take advantage of
platelets as a safe transport system to reach the liver, where platelet
activation further enhances the interaction of platelets and liver
cells. This interaction prolongs the time for potential infection of
liver tissue by the virus (46).
Virus-mediated activation of platelets and subsequent platelet-
derived cytokine release not only protects the host but may also
have unwanted implications for the host. While several reports
indicate that CXCL4 is a broad-spectrum suppressor of HIV infec-
tion, one report indicates that platelet CXCL4 can also facilitate
human macrophage infection with HIV-1 and potentiates virus
replication (110). Furthermore,CXCL4 has been shown to mediate
liver fibrosis in experimental mouse models (111), indicating that
this chemokine could play a role in platelet-mediated acceleration
of hepatitis-induced liver fibrosis.
Platelet-derived serotonin results in a delayed entry of acti-
vated cytotoxic T-lymphocytes into the liver, which slows down
virus control and supports virus persistence in the liver (112).
This results in aggravation of virus-induced immunopathology.
Megakaryocyte infection and subsequent modulation of
platelet function by CMV have been speculated to be a reason
for graft failure in allergenic bone marrow transplantation (25).
BLEEDING AND THROMBOTIC COMPLICATIONS IN
RESPONSE TO VIRAL INFECTION
Primary and secondary hemostasis work tightly together. Imbal-
ances of either system result in impaired function of the other.
Activation of the coagulation cascade has been observed in various
virus infections, including HIV, dengue, and Ebola virus infection,
and might provide a host defense mechanism to limit pathogen
dissemination (53). Changes in the activation of the coagulation
cascade and modulation of platelet count and function, which are
also observed during viral infections, lead to an increased risk
of disseminated vascular coagulation (DIC), deep vein throm-
bosis (DVT) thrombosis, and hemorrhage in infected patients
(38). Thrombocytopenia is a common result of viral infections
and associated with an increased bleeding risk. Approximately
10% of HIV positive patients and up to 60% of patients with
acquired immunodeficiency syndrome (AIDS) suffer from throm-
bocytopenia, which can lead to severe bleedings in these patients
(30). In many viral infections, platelet function and aggregation in
response to different agonists are diminished (25), causing bleed-
ing complications in viral hemorrhagic fevers (VHF) (51). VHF
outbreaks lead to the deaths of thousands of people every year
and are caused by different enveloped RNA viruses, which include
Arenaviridae (e.g., Lassa virus), Bunyaviridea (e.g., hantavirus),
Filioviridae (e.g., Marburg and Ebola virus), and Flaviviridae (e.g.,
dengue virus).
Of note, it was recently shown that a reduction in platelet
count of more than 85% is necessary for hemorrhages to occur,
indicating that a very low percentage of platelets are sufficient
to maintain vascular integrity (109). In an LCMV model, it was
demonstrated that even severe thrombocytopenic mice develop
only local hemorrhages at sites of inflammation and that LCMV-
dependent bleedings are a result of IFNα/β signaling-induced
platelet dysfunction (68). Mice lacking functional IFNα/β recep-
tor show less severe anemia and hemorrhages due to restored
platelet aggregation capacity during LCMV infection (68). This
indicates that platelet dysfunction has more tremendous effects
than thrombocytopenia in these pathologies. Of note, many
VHF viruses inhibit platelet function. Junin virus, causative
of Argentinean hemorrhagic fever, induces IFNα/β signaling-
dependent decrease in platelet production and function (69).
Ebola virus also induces an increase in IFNα, which corre-
lated with increased fatality (113). Ebola infection further trig-
gers TF expression, which is associated with Ebola hemorrhagic
fever (114). Hantavirus and Lassavirus also abrogate platelet
responses via plasma-mediated platelet inhibition and/or direct
interaction (37, 115).
Although thrombocytopenia is frequently observed in patients
with dengue infections, bleedings are rare. However, if bleedings
do occur they are associated with high mortality risk. Of note,
in dengue virus-infected patients, platelet count does not pre-
dict bleeding risk. However, systemic platelet activation might
contribute to the pro-coagulatory state in these patients, which fre-
quently develop DIC (67). Moreover, elevated platelet activation
is associated with plasma leakage (116). H1N1 influenza infection
enhances activation of circulating platelets (117) and results in
increased events of thrombosis (118).
In line with the observation that platelet dysfunction increases
the risk of hemorrhages and therefore mortality, it has been
demonstrated that pharmacological inhibition of either platelets
or the coagulation cascade increases the mortality of H1N1-
infected mice (53). Thus, aspirin treatment, which inhibits platelet
activation via inhibition of cyclooxygenase and subsequent TxA2
production, has been hypothesized to have worsened the incidence
and severity of the influenza pandemics in the 1910s (119).
Taken together, viruses can either enhance platelet activation
resulting in pro-thrombotic events or diminish platelet responses
thereby leading to bleeding complications. Platelet count alone
does not seem to be sufficient to predict adverse platelet effects
and parameters like platelet activation and reactivity might be
more accurate to predict thrombotic or bleeding risks in patients.
PLATELET–VIRUS INTERPLAY IN CARDIOVASCULAR DISEASE
Platelets are responsible for the lethal consequences of cardiovas-
cular disease but emerging evidence suggests that they also play
a role in the initiation and progression of atherosclerosis. Sev-
eral viruses have been associated with cardiovascular disease and
herpes simplex virus (HSV), HIV, CMV, HCV, EBV as well as
influenza DNA, and/or protein has been found in atherosclerotic
plaques (120, 121). Large cohort studies indicate that seroposi-
tivity for CMV or HCV represent an independent risk marker
for cardiovascular diseases (122, 123), while other studies could
not confirm this observation (121). CMV and HCV are further
associated with increased graft rejection rates, restenosis following
coronary angioplasty and transplant vascular sclerosis, indicat-
ing that latent virus re-activates during immunosuppression and
contributes to adverse effects (121).
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In animal studies, CMV increased T-lymphocyte influx into
plaques (124) and neutrophil extravasation, which is further
supported in the presence of platelets (32). Influenza virus infec-
tion correlates with acute coronary syndromes and myocardial
infarction (125), while influenza seropositivity and cardiovascu-
lar disease show no clear correlation (121). Animal experiments
revealed that influenza triggers inflammatory and thrombotic
responses in atherosclerotic plaques (126) and reverses the pro-
tective role of high-density lipoproteins (127). Both mechanisms
are likely to modulate platelet function and reactivity.
There is some discrepancy regarding the strength of data
regarding HSV infection and cardiovascular disease and despite
its pro-inflammatory responses, a negative association between
EBV infection and cardiovascular disease has been observed.
Moreover, the association between HIV infection and cardio-
vascular disease remains controversial and anti-retroviral therapy
itself alters platelet function (128) and represents an independent
risk factor for atherosclerosis (121). Further studies are war-
ranted to evaluate the contribution of platelet–virus interactions
in cardiovascular disease.
CONCLUSION
Platelets and their released products have been reported to directly
and indirectly suppress infection but also to support virus persis-
tence in response to certain viruses, making platelets a double-
edged sword during viral infections. Platelets are involved in a
variety of complications in response to viral infection but also
fulfill a pivotal role in retaining adequate host responses. Throm-
bocytopenia is a common complication in several viral infections
and viruses exert various strategies to mediate platelet decay. The
question, if thrombocytopenia is a viral strategy to evade immune
responses or if it also has host protecting functions, seems to
depend on the virus variant and the underlying pathology. Further
studies are warranted to fully understand the role of platelets in
viral infections and to gain a clear understanding of the effects of
anti-platelet therapies in viral infections. These studies will help us
to predict the benefit or drawback of platelets and their inhibition
during viral infections.
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